Nektar Therapeutics, a research-based biopharmaceutical company, discovers and develops drug candidates for cancer, auto-immune disease, and chronic pain based on its PEGylation and polymer conjugate technology platforms in the United States. The company offers ONZEALD, a topoisomerase I inhibitor that is in Phase III clinical trial for advanced metastatic breast cancer in patients with brain metastases; NKTR-181, an orally-available mu-opioid analgesic molecule, which is in Phase III clinical trial for moderate to severe chronic pain; NKTR-214, a cytokine immunostimulatory therapy that is in Phase I/II to treat cancer; NKTR-358, which is in Phase I to treat autoimmune diseases; and NKTR-262 for solid tumors, as well as NKTR-255 that is under research/preclinical stage for immuno-oncology. It is also developing MOVANTIK for opioid-induced constipation in adult patients with chronic non-cancer pain, and who have an inadequate response to laxatives; ADYNOVATE for hemophilia A; Somavert to treat acromegaly; and Neulasta for treating neutropenia. In addition, the company develops PEG-INTRON for the treatment of hepatitis-C; Macugen for age-related macular degeneration; CIMZIA to treat rheumatoid arthritis, Crohn's disease, and psoriasis/ankylosing spondylitis; and MIRCERA for anemia related to chronic kidney disease in patients on and not on dialysis. Further, it is developing SEMPRANA to treat migraine; dapirolizumab pegol for systemic lupus erythematosus; PEGPH20 for ancreatic, non-small cell lung cancer, and other tumor types; and longer-acting blood clotting proteins for hemophilia. The company has collaboration agreements with AstraZeneca AB, Shire plc, Pfizer Inc., Amgen Inc., Merck & Co., Inc., Valeant Pharmaceuticals International, Inc., UCB Pharma S.A., F. Hoffmann-La Roche Ltd, Allergan, Inc., Halozyme Therapeutics, Inc., Baxalta Incorporated, and Bristol-Myers Squibb Company. The company was founded in 1990 and is headquartered in San Francisco, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
SymbolNASDAQ:NKTR
CUSIP64026810
Phone415-482-5300
Debt
Debt-to-Equity Ratio4.21
Current Ratio4.16
Quick Ratio4.03
Price-To-Earnings
Trailing P/E Ratio-96.09
Forward P/E Ratio15.64
P/E GrowthN/A
Sales & Book Value
Annual Sales$30.71 million
Price / Sales294.97
Cash FlowN/A
Price / CashN/A
Book Value$0.56 per share
Price / Book94.38
Profitability
EPS (Most Recent Fiscal Year)($0.55)
Net Income$-96,690,000.00
Net Margins-40.07%
Return on Equity-202.41%
Return on Assets-22.92%
Miscellaneous
Employees509
Outstanding Shares171,400,000
Nektar Therapeutics (NASDAQ:NKTR) Frequently Asked Questions
What is Nektar Therapeutics' stock symbol?
Nektar Therapeutics trades on the NASDAQ under the ticker symbol "NKTR."
How were Nektar Therapeutics' earnings last quarter?
Nektar Therapeutics (NASDAQ:NKTR) issued its earnings results on Thursday, May, 10th. The biopharmaceutical company reported ($0.60) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.52) by $0.08. The biopharmaceutical company earned $38.02 million during the quarter, compared to analyst estimates of $35.59 million. Nektar Therapeutics had a negative net margin of 40.07% and a negative return on equity of 202.41%. The business's quarterly revenue was up 53.7% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.42) earnings per share. View Nektar Therapeutics' Earnings History.
When is Nektar Therapeutics' next earnings date?
What price target have analysts set for NKTR?
12 brokerages have issued 1 year target prices for Nektar Therapeutics' shares. Their predictions range from $20.00 to $125.00. On average, they anticipate Nektar Therapeutics' share price to reach $81.1818 in the next twelve months. View Analyst Ratings for Nektar Therapeutics.
What are Wall Street analysts saying about Nektar Therapeutics stock?
Here are some recent quotes from research analysts about Nektar Therapeutics stock:
- 1. Mizuho analysts commented, "We believe Keytruda’s data reinforces our thesis on Nektar. Assuming positive data at ASCO, we believe BMS would be inclined to make a bid for Nektar given its deteriorating market position relative to Merck." (4/17/2018)
- 2. According to Zacks Investment Research, "Nektar has a promising pipeline, with several updates lined up for the next several quarters. Additionally, regular partnerships have enhanced the company’s financial position. Nektar stands to receive significant sales milestone payment plus royalties for Movantik under the license agreement with AstraZeneca. Also, its recent codevelopment deal with Lilly for NKTR-358 is encouraging. On the flip side, Nektar relies heavily on partners for revenues. Partnership-related setbacks may thus weigh heavily on the company, while disappointing products sales could leave an adverse impact on its financial results. Moreover, competition from various pharmaceutical and biotechnology companies is another matter of concern. Shares of the company have significantly outperformed the industry in the last one year." (2/21/2018)
Who are some of Nektar Therapeutics' key competitors?
Some companies that are related to Nektar Therapeutics include Regeneron Pharmaceuticals (REGN), Shiseido (SSDOY), Takeda Pharmaceutical (TKPYY), ASTELLAS PHARMA/ADR (ALPMY), Alexion Pharmaceuticals (ALXN), Teva Pharmaceutical Industries (TEVA), Mylan (MYL), BioMarin Pharmaceutical (BMRN), GRIFOLS S A/S (GRFS), UCB (UCBJF), Ono Pharmaceutical (OPHLF), Merck KGaA (MKGAF), Jazz Pharmaceuticals (JAZZ), Perrigo (PRGO) and Alnylam Pharmaceuticals (ALNY).
Who are Nektar Therapeutics' key executives?
Nektar Therapeutics' management team includes the folowing people:
- Mr. Howard W. Robin, CEO, Pres & Director (Age 65)
- Mr. Gil M. Labrucherie, Sr. VP & CFO (Age 46)
- Mr. John Nicholson, Sr. VP & COO (Age 66)
- Dr. Maninder Hora, Sr. VP of Pharmaceutical Devel. and Chief Technical Operations Officer (Age 64)
- Ms. Jillian B. Thomsen, Sr. VP of Fin. & Chief Accounting Officer (Age 52)
Has Nektar Therapeutics been receiving favorable news coverage?
News stories about NKTR stock have been trending somewhat positive recently, Accern Sentiment reports. The research firm ranks the sentiment of media coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Nektar Therapeutics earned a media sentiment score of 0.07 on Accern's scale. They also assigned media stories about the biopharmaceutical company an impact score of 46.21 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the next few days.
Who are Nektar Therapeutics' major shareholders?
Nektar Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (8.45%), OppenheimerFunds Inc. (6.26%), Northern Trust Corp (1.52%), JPMorgan Chase & Co. (0.74%), Summit Trail Advisors LLC (0.73%) and Schwab Charles Investment Management Inc. (0.68%). Company insiders that own Nektar Therapeutics stock include Christopher A Kuebler, Gil M Labrucherie, Howard W Robin, Ivan P Gergel, Jillian B Thomsen, John Nicholson, Lutz Lingnau, Maninder Hora, R Scott Greer, Robert Chess, Roy A Whitfield and Stephen K Doberstein. View Institutional Ownership Trends for Nektar Therapeutics.
Which institutional investors are selling Nektar Therapeutics stock?
NKTR stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., OppenheimerFunds Inc., PointState Capital LP, Westfield Capital Management Co. LP, Principal Financial Group Inc., Principal Financial Group Inc., Federated Investors Inc. PA and Public Employees Retirement Association of Colorado. Company insiders that have sold Nektar Therapeutics company stock in the last year include Christopher A Kuebler, Gil M Labrucherie, Howard W Robin, Ivan P Gergel, Jillian B Thomsen, John Nicholson, Lutz Lingnau, Maninder Hora, R Scott Greer, Robert Chess and Stephen K Doberstein. View Insider Buying and Selling for Nektar Therapeutics.
Which institutional investors are buying Nektar Therapeutics stock?
NKTR stock was acquired by a variety of institutional investors in the last quarter, including Summit Trail Advisors LLC, Northern Trust Corp, Frontier Capital Management Co. LLC, Franklin Resources Inc., Guggenheim Capital LLC, Scout Investments Inc., Schwab Charles Investment Management Inc. and Van ECK Associates Corp. Company insiders that have bought Nektar Therapeutics stock in the last two years include R Scott Greer and Roy A Whitfield. View Insider Buying and Selling for Nektar Therapeutics.
How do I buy shares of Nektar Therapeutics?
Shares of NKTR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Nektar Therapeutics' stock price today?
One share of NKTR stock can currently be purchased for approximately $52.85.
How big of a company is Nektar Therapeutics?
Nektar Therapeutics has a market capitalization of $9.57 billion and generates $30.71 million in revenue each year. The biopharmaceutical company earns $-96,690,000.00 in net income (profit) each year or ($0.55) on an earnings per share basis. Nektar Therapeutics employs 509 workers across the globe.
How can I contact Nektar Therapeutics?
Nektar Therapeutics' mailing address is 455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO CA, 94158. The biopharmaceutical company can be reached via phone at 415-482-5300 or via email at [email protected]
MarketBeat Community Rating for Nektar Therapeutics (NKTR)
MarketBeat's community ratings are surveys of what our community members think about Nektar Therapeutics and other stocks. Vote "Outperform" if you believe NKTR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NKTR will underperform the S&P 500 over the long term. You may vote once every thirty days.
